How menopause affects oral health, and what we can do about it

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 8, 2009, Pages 467-475

  Buencamino, Maria Clarinda A ^a   Palomo, Leena ^b   Thacker, Holly L ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Case School of Dental Medicine   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

DISEASE PREDISPOSITION; FEMALE; HEALTH; HUMAN; MENOPAUSE; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

DISEASE SUSCEPTIBILITY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; ORAL HEALTH; OSTEOPOROSIS, POSTMENOPAUSAL; PERIODONTAL DISEASES;

EID: 70350441794     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.08095     Document Type: Review

References (53)

1. North American Menopause Society. Menopause Practice: A Clinician's Guide. 3rd ed; 2007.
2. Krall EA, Garcia RI, Dawson-Hughes B. Increased risk of tooth loss is related to bone loss at the whole body, hip and spine. Calcif Tissue Int 1996; 59:433-437.
3. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 1990; 63:218-222.
4. Kribbs PJ, Chesnut CH 3rd, Ott SM, Kilcoyne RF. Relationship between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 1989; 62:703-707.
5. Kribbs PJ, Chestnut CH 3rd, Ott SM, Kilcyne RE. Relationship between mandibular and skeletal bone in a population of normal women. J Prosthet Dent 1990; 63:86-89.
6. Kribbs PJ, Smith DE, Chestnut CH 3rd. Oral findings in osteoporosis. Part II: relationship between residual ridge and alveolar bone resorption and generalized skeletal osteopenia. J Prosthet Dent 1983; 50:719-724.
7. von Wowern N, Klausen B, Kollerup G. Osteoporosis: a risk factor in periodontal disease. J Periodontol 1994; 65:1134-1138.
8. Wactawski-Wende J, Grossi SG, Trevisan M, et al. The role of osteopenia in oral bone loss and periodontal disease. J Peridontol 1996; 67(suppl 10):1076-1084.
9. Ronderos M, Jacobs DR, Himes JH, Pihlstrom BL. Associations of periodontal disease with femoral bone mineral density and estrogen replacement therapy: cross-sectional evaluation of US adults from the NHANES III. J Clin Periodontol 2000; 27:778-86.
10. American Dental Association Council on Access, Prevention and Interprofessional Relations. Women's Oral Health Issues. November. 2006.
11. Jeffcoat MK, Lewis CE, Reddy MS, Wang CY, Redford M. Post-menopausal bone loss and its relationship to oral bone loss. Periodontol 2000 2000; 23:94-102.
12. Famili P, Cauley J, Suzuki JB, Weyant R. Longitudinal study of periodontal disease and edentulism with rates of bone loss in older women. J Periodontol 2005; 76:11-15.
13. Pilgram TK, Hildebolt CF, Yokoyama N, et al. Relationships between longitudinal changes in radiographic alveolar bone height and probing depth measurements: data from postmenopausal women. J Periodontol 1999; 70:829-833.
14. Jeffcoat MK, Lewis CE, Reddy MS, et al. Oral bone loss and systemic osteopenia, osteoporosis. In Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. New York Academic Press 1996:969-990.
15. Klemetti E, Collin HL, Forss H, Markkanen H, Lassila V. Mineral status of skeletal and advanced periodontal disease. J Clin Periodontol 1994; 21:184-188.
16. Hildebolt CF. Osteoporosis and oral bone loss. Dentomaxillofac Radiol 1997; 26:3-15.
17. Tezal M, Wactawski-Wende J, Grossi SG, Ho AW, Dunford R, Genco RJ. The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000; 71:1492-1498.
18. Taguchi A, Tanimoto K, Suei Y, Ohama K, Wada T. Relationship between the mandibular and lumbar vertebral bone mineral density at different postmenopausal stages. Dentomaxillofac Radiol 1996; 25:130-135.
19. Payne JB, Reinhardt RA, Nummikoski PV, Patil KD. Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 1999; 10:34-40.
20. Payne JB, Zachs NR, Reinhardt RA, Nummikoski PV, Patil K. The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. J Periodontol 1997; 68:24-31.
21. Civitelli R, Pilgram TK, Dotson M, et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement: a randomized, double blind, placebo-controlled trial. Arch Intern Med 2002; 162:1409-1415.
22. Albandar JM, Kingman A. Gingival recession, gingival bleeding, and dental calculus in adults 30 years of age and older in the United States, 1988-19J Periodontol 1999; 70:30-43.
23. Norderyd OM, Grossi SG, Machtel EE, et al. Periodontal status of women taking postmenopausal estrogen supplementation. J Periodontol 1993; 64:957-962.
24. Jacobs R, Ghyselen J, Koninckx P, van Steenberghe D. Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy. Eur J Oral Sci 1996; 104:10-16.
25. Meisel P, Reifenberger J, Haase R, Nauck M, Bandt C, Kocher T. Women are periodontally healthier than men, but why don't they have more teeth than men? Menopause 2008; 15:270-275.
26. Genco RJ, Grossi SG. Is estrogen deficiency a risk factor for periodontal disease? Compend Contin Educ Dent Suppl 1998; 22:S23-S29.
27. Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. Arch Intern Med 1995; 155:2325-2329.
28. Krall EA, Dawson-Hughes B, Hannan MT, Wilson PW, Kiel DP. Postmenopausal estrogen replacement and tooth retention. Am J Med 1997; 102:536-542.
29. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc 1996; 127:370-377.
30. Taguchi A, Sanada M, Suei Y, et al. Effect of estrogen use on tooth retention, oral bone height, and oral bone porosity in Japanese postmenopausal women. Menopause 2004; 11:556-562.
31. Pacifici R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11:1043-1051.
32. Pacifici R. Is there a causal role for IL-1 in postmenopausal bone loss? Calcif Tissue Int 1992; 50:295-299.
33. Girasole G, Jilka RL, Passeri G, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992; 89:883-891.
34. Pacifici R, Brown C, Pusheck E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991; 88:5134-5138.
35. Brennan RM, Genco RJ, Wilding GE, Hovey KM, Trevisan M, Wactawski-Wende J. Bacterial species in subgingival plaque and oral bone loss in postmenopausal women. J Periodontol 2007; 78:1051-1061.
36. Chestnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausa losteoporosis. J Bone Miner Res 2004; 19:1241-1249.
37. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-1541.
38. McClung MR, Geusen P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340.
39. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11:83-91.
40. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-1809.
41. Palomo L, Bissada N, Liu J. Periodontal assessment of postmenopausal women receiving risedronate. Menopause 2005; 12:685-690.
42. Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol 2004; 75:1579-1585.
43. Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 2007; 9:70-76.
44. Carey JJ, Palomo L. Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med 2008; 75:871-879.
45. Woo SB, Hellstein JW, Kalamare JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761.
46. Dodson TB, Raje NS, Caruso PA, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 9-20A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med 2008; 358:1283-1291.
47. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofacial Surg 2004; 62:527-534.
48. Palomo L, Liu J, Bissada NF. Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy. Expert Opin Pharmacother 2007; 8:309-315.
49. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000; 42:175-195.
50. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37:285-290.
51. American Dental Association Council on Scientific Affairs Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations J Am Dent Assoc 2006; 137:1144-1150
52. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofacial Surg 2007; 65:369-376
53. Grbic JT, Landesberg R, Lin SQ, et al, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial J Am Dent Assoc 2008; 139:32-40